Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is conducting a Phase 3b clinical study titled ‘A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab.’ The study aims to evaluate the safety and effectiveness of risankizumab versus vedolizumab in treating adults with moderate to severe ulcerative colitis who have not previously received targeted therapies. This study is significant as it may offer new insights into treatment options for this inflammatory bowel disease.
The study tests two drugs: Risankizumab, administered intravenously and subcutaneously, and Vedolizumab, administered intravenously. Both are approved treatments for ulcerative colitis, and the study seeks to compare their efficacy and safety.
The study design is interventional, with participants randomly assigned to one of the two treatment groups. It follows a parallel intervention model with no masking, focusing primarily on treatment outcomes.
The study began on June 17, 2025, with an estimated completion timeline of 69 to 71 weeks for participants. The latest update was submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical update could impact AbbVie’s stock performance, as positive results may boost investor confidence and market position. The study’s outcome could also influence the competitive landscape in the ulcerative colitis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.